Galapagos NV (NASDAQ:GLPG) Receives Consensus Rating of “Reduce” from Analysts

Galapagos NV (NASDAQ:GLPG) has been assigned a consensus recommendation of “Reduce” from the nine analysts that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $31.3333.

GLPG has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Galapagos in a report on Wednesday, October 8th. Leerink Partners set a $40.00 price objective on Galapagos and gave the company an “outperform” rating in a research report on Tuesday, October 21st. Sanford C. Bernstein started coverage on shares of Galapagos in a report on Wednesday, November 26th. They issued a “hold” rating for the company. Wall Street Zen upgraded shares of Galapagos from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Finally, Leerink Partnrs raised shares of Galapagos from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 22nd.

Institutional Investors Weigh In On Galapagos

A number of institutional investors have recently bought and sold shares of GLPG. ABC Arbitrage SA purchased a new position in shares of Galapagos in the first quarter valued at about $333,000. Tejara Capital Ltd purchased a new position in Galapagos in the 1st quarter worth approximately $1,351,000. American Century Companies Inc. boosted its stake in Galapagos by 7.7% in the 1st quarter. American Century Companies Inc. now owns 27,839 shares of the biotechnology company’s stock worth $699,000 after purchasing an additional 1,987 shares during the period. OLD Mission Capital LLC purchased a new stake in Galapagos during the 1st quarter valued at approximately $1,885,000. Finally, Vestal Point Capital LP raised its position in shares of Galapagos by 11.1% during the first quarter. Vestal Point Capital LP now owns 200,000 shares of the biotechnology company’s stock valued at $5,024,000 after buying an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Galapagos Price Performance

Shares of GLPG stock opened at $31.77 on Thursday. The company has a market cap of $2.09 billion, a price-to-earnings ratio of -20.24 and a beta of 0.18. Galapagos has a 1 year low of $22.36 and a 1 year high of $37.78. The firm has a fifty day moving average price of $32.45 and a 200-day moving average price of $31.29.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.